GC
CGTX icon

Gratus Capital’s Cognition Therapeutics CGTX Stock Holding History

Gratus Capital’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		$30.6K Hold
18,424
– – ﹤0.01% 373
2024
Q1 		$33.5K Buy
+18,424
New +$38K ﹤0.01% 319

Other funds holding CGTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
TIM
Timelo Investment Management Aurora, Ontario, Canada $127M AUM 23.73% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AFG
American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
KAS
Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return

Gratus Capital's CGTX Position: Q2 2024 in Review

Gratus Capital held its Cognition Therapeutics (CGTX) position steady in Q2 2024 at 18,424 shares worth $30.6K. The position accounts for ﹤0.01% of the portfolio, ranked #373.

Gratus Capital first reported a position in CGTX in Q1 2024 and has held it in 2 quarters since. The position peaked at $33.5K in Q1 2024. 46 funds tracked by Wall St. Rank hold CGTX as of Q2 2024.

  • Gratus Capital held 18,424 shares of Cognition Therapeutics worth $30.6K as of Q2 2024.
  • Gratus Capital left its Cognition Therapeutics share count unchanged in Q2 2024.
  • Cognition Therapeutics made up ﹤0.01% of Gratus Capital's portfolio in Q2 2024, its #373 holding.
  • Gratus Capital first reported a position in Cognition Therapeutics in Q1 2024 and has held it in 2 quarters since.
  • Gratus Capital's Cognition Therapeutics position peaked at $33.5K in Q1 2024.
  • 46 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q2 2024.

Based on Gratus Capital's 13F filing for Q2 2024, filed 25 Jul 2024.